Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study.

IF 2.2 Q3 INFECTIOUS DISEASES Journal of the International Association of Providers of AIDS Care Pub Date : 2024-01-01 DOI:10.1177/23259582241269837

Cassidy A Gutner, Marc van der Valk, Joaquin Portilla, Eliette Jeanmaire, Leïla Belkhir, Thomas Lutz, Rebecca DeMoor, Rekha Trehan, Jenny Scherzer, Miguel Pascual-Bernáldez, Mounir Ait-Khaled, Beatriz Hernandez, Annemiek de Ruiter, Savita Bakhshi Anand, Emma L Low, Monica Hadi, Nicola Barnes, Nick Sevdalis, Perry Mohammed, Maggie Czarnogorski

{"title":"Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study.","authors":"Cassidy A Gutner, Marc van der Valk, Joaquin Portilla, Eliette Jeanmaire, Leïla Belkhir, Thomas Lutz, Rebecca DeMoor, Rekha Trehan, Jenny Scherzer, Miguel Pascual-Bernáldez, Mounir Ait-Khaled, Beatriz Hernandez, Annemiek de Ruiter, Savita Bakhshi Anand, Emma L Low, Monica Hadi, Nicola Barnes, Nick Sevdalis, Perry Mohammed, Maggie Czarnogorski","doi":"10.1177/23259582241269837","DOIUrl":null,"url":null,"abstract":"Introduction: CARISEL is an implementation-effectiveness \"hybrid\" study examining the perspectives of people living with HIV-1 (patient study participants [PSPs]) on cabotegravir (CAB) plus rilpivirine (RPV) long-acting (LA) dosed every 2 months (Q2M) across 5 European countries.Methods: PSPs completed questionnaires on acceptability (Acceptability of Intervention Measure), appropriateness (Intervention Appropriateness Measure), and feasibility (Feasibility of Intervention Measure) at their first (Month [M] 1), third (M4), and seventh (M12) injection visits. Semistructured qualitative interviews were also conducted.Results: Overall, 437 PSPs were enrolled, of whom 430 received treatment. Median (interquartile range) age was 44 (37-51) years, 25.3% (n = 109/430) were female (sex at birth), and 21.9% (n = 94/430) were persons of color. Across time points, PSPs found CAB + RPV LA highly acceptable, appropriate, and feasible (mean scores ≥4.47/5). Qualitative data supported these observations.Conclusions: PSPs found CAB + RPV LA Q2M to be an acceptable, appropriate, and feasible treatment option.","PeriodicalId":17328,"journal":{"name":"Journal of the International Association of Providers of AIDS Care","volume":"23 ","pages":"23259582241269837"},"PeriodicalIF":2.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367594/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International Association of Providers of AIDS Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/23259582241269837","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: CARISEL is an implementation-effectiveness "hybrid" study examining the perspectives of people living with HIV-1 (patient study participants [PSPs]) on cabotegravir (CAB) plus rilpivirine (RPV) long-acting (LA) dosed every 2 months (Q2M) across 5 European countries.

Methods: PSPs completed questionnaires on acceptability (Acceptability of Intervention Measure), appropriateness (Intervention Appropriateness Measure), and feasibility (Feasibility of Intervention Measure) at their first (Month [M] 1), third (M4), and seventh (M12) injection visits. Semistructured qualitative interviews were also conducted.

Results: Overall, 437 PSPs were enrolled, of whom 430 received treatment. Median (interquartile range) age was 44 (37-51) years, 25.3% (n = 109/430) were female (sex at birth), and 21.9% (n = 94/430) were persons of color. Across time points, PSPs found CAB + RPV LA highly acceptable, appropriate, and feasible (mean scores ≥4.47/5). Qualitative data supported these observations.

Conclusions: PSPs found CAB + RPV LA Q2M to be an acceptable, appropriate, and feasible treatment option.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

患者参与者对长效卡博特拉韦和利匹韦林实施情况的看法：欧洲卡博替拉韦和利匹韦林实施研究（CARISEL）的结果。

简介：CARISEL 是一项实施效果 "混合 "研究：CARISEL是一项实施效果 "混合 "研究，考察了欧洲5个国家的HIV-1感染者（患者研究参与者[PSPs]）对卡博替拉韦（CAB）加利匹韦林（RPV）长效（LA）每2个月（Q2M）用药的看法：PSPs 在第一次（Month [M] 1）、第三次（M4）和第七次（M12）注射时填写了关于可接受性（干预可接受性测量）、适当性（干预适当性测量）和可行性（干预可行性测量）的问卷。此外，还进行了半结构化定性访谈：总共有 437 名 PSP 参与，其中 430 人接受了治疗。年龄中位数（四分位数间距）为 44（37-51）岁，25.3%（n = 109/430）为女性（出生时性别），21.9%（n = 94/430）为有色人种。在各个时间点，PSP 都认为 CAB + RPV LA 非常可接受、合适和可行（平均得分≥4.47/5）。定性数据支持这些观察结果：PSPs 认为 CAB + RPV LA Q2M 是一种可接受的、适当的和可行的治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊